Last Updated: November 16, 2026

Details for Patent: 10,864,194

« Back to Dashboard


Which drugs does patent 10,864,194 protect, and when does it expire?

Patent 10,864,194 protects SOHONOS and is included in one NDA.

This patent has twenty-nine patent family members in eighteen countries.

Summary for Patent: 10,864,194
Title:Methods for treating heterotopic ossification
Abstract:The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Inventor(s):Clarissa Desjardins, Donna Roy GROGAN, Jeffrey Neal PACKMAN, Mark Harnett
Assignee: Clementia Pharmaceuticals Inc
Application Number:US16/308,012
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 10,864,194: Palovarotene Dosing Claims, Patent Scope, Expiration and Generic Risk

U.S. Patent No. 10,864,194 protects a flare-up-responsive palovarotene regimen for reducing heterotopic ossification in patients with fibrodysplasia ossificans progressiva, or FOP. The core regimen is 5 mg daily when the patient has no flare-up, followed by 20 mg daily for approximately 28 days after a flare-up begins, then 10 mg daily for up to 112 days. The patent is assigned to Clementia Pharmaceuticals, now part of Ipsen, and is directed to treatment methods rather than palovarotene composition, formulation, or manufacturing claims.

The patent has substantial relevance to Sohonos, Ipsen’s FDA-approved palovarotene product. Its commercial strength comes from the close overlap between the claimed regimen and the FDA-approved flare-up dosing schedule. Its principal weakness is claim narrowness: infringement requires proof of the specified patient condition, dosing sequence, timing, flare-up criteria, and, for several claims, patient weight or skeletal maturity.

What does U.S. Patent 10,864,194 cover?

The patent covers methods of reducing heterotopic ossification in a subject with FOP by using two dosing states:

  1. A chronic or quiescent-period dose of 5 mg daily when the subject is not experiencing a flare-up symptom.
  2. A flare-up regimen consisting of:
    • 20 mg daily for 20 to 40 days; followed by
    • 10 mg daily for 14 to 112 days.

Independent claim 1 is the broadest principal claim. Independent claim 3 narrows the regimen to the commercially important schedule of 5 mg daily during quiescence, 20 mg daily for 28 days during a flare-up, and 10 mg daily for at least 56 days thereafter.

Claim feature Claim 1 Claim 3
Disease FOP FOP
Therapeutic objective Reducing heterotopic ossification Reducing heterotopic ossification
Quiescent dose 5 ± 0.5 mg daily 5 mg daily
Flare-up dose 20 ± 1.0 mg daily 20 mg daily
Initial flare-up duration 20 to 40 days 28 days
Follow-on dose 10 ± 1.0 mg daily 10 mg daily
Follow-on duration 14 to 112 days At least 56 days
Salt form Included Included
Weight limitation None in claim 1 None in claim 3
Skeletal maturity limitation None in claim 1 None in claim 3

The claimed dose tolerances translate into the following practical ranges:

  • 5 ± 0.5 mg: 4.5 to 5.5 mg
  • 20 ± 1.0 mg: 19 to 21 mg
  • 10 ± 1.0 mg: 9 to 11 mg

The exact-dose language in claim 3 is potentially more restrictive than the tolerance language in claim 1. A regimen using 5 mg, 20 mg, and 10 mg falls within both claim structures, assuming all other limitations are met.

How do claims 1 and 3 differ?

Claims 1 and 3 are separate independent claims with overlapping but different dosing limitations.

Claim 1 permits:

  • A 20 mg flare-up dose for 20 to 40 days.
  • A subsequent 10 mg dose for 14 to 112 days.
  • A broader 10 mg follow-on duration than claim 3.
  • Dosing within specified numerical tolerances.

Claim 3 requires:

  • Exactly 20 mg daily for 28 days.
  • Exactly 10 mg daily after the 28-day period.
  • At least 56 days of follow-on dosing.

Claim 3 is narrower in duration but closely tracks the dosing schedule reflected in the Sohonos prescribing information. Claims 20 through 30 depend from claim 3 and add further restrictions involving 56-day treatment, an additional 28 days if symptoms continue, patient weight, antihistamines, emollients, symptom categories, and palovarotene or its salt form.

What are the limitations of the dependent claims?

The dependent claims create multiple fallback positions.

Claims Added limitation
2 10 mg phase lasts 14 to 84 days
4 10 mg phase lasts 84 days
5 10 mg phase lasts 14 to 56 days
6 10 mg phase lasts 56 days
7 56 days, plus 28 additional days if symptoms continue
8 10 mg phase lasts 112 days
9 20 mg phase lasts 28 ± 4 days
10 20 mg phase lasts exactly 28 days
11 Subject weighs more than 60 kg
12 Skeletal maturity is at least 90%
13-15 Antihistamine is administered, topically or systemically
16 Emollient is administered to the skin
17 Flare-up symptom is swelling, pain, erythema, warmth, stiffness, or reduced range of motion
18-19 Active ingredient is palovarotene or a pharmaceutically acceptable salt
20-21 Claim 3’s 10 mg phase lasts 56 days, with optional additional 28 days
22-23 Claim 3 subject weighs more than 60 kg or has at least 90% skeletal maturity
24-27 Antihistamine or emollient is added to the claim 3 regimen
28 Claim 3 flare-up symptom is from the specified symptom group
29-30 Palovarotene or its pharmaceutically acceptable salt is used

The weight limitation is commercially significant because the FDA-approved regimen for patients weighing at least 60 kg corresponds closely to the 5 mg chronic dose and 20/10 mg flare-up sequence. The claims do not expressly require a particular sex or age, although the approved indication imposes age and sex restrictions.

What is the scope of the flare-up limitation?

The claims require treatment during a period when the subject is experiencing at least one flare-up symptom. Claim 17 and claim 28 identify the relevant symptoms as:

  • Swelling
  • Pain
  • Erythema
  • Warmth
  • Stiffness
  • Decreased range of motion

This limitation is central to infringement. A product label or clinical protocol that merely recommends palovarotene for FOP without directing the claimed flare-up transition may present a weaker induced-infringement case. Conversely, a label instructing patients to increase the dose after swelling, pain, warmth, or reduced mobility would closely align with the patent claims.

The claims do not require a particular diagnostic test, imaging result, anatomical site, or minimum severity threshold for the flare-up. The absence of those limitations broadens the practical trigger for the regimen, although indefiniteness, written-description, enablement, and claim-construction issues could arise if a dispute concerned borderline symptoms.

What is the FDA status of palovarotene and Sohonos?

The FDA approved Sohonos capsules for reducing the volume of new heterotopic ossification in females aged 8 years and older and males aged 10 years and older with FOP. The product is approved in multiple capsule strengths, including 1 mg, 1.5 mg, 2.5 mg, 5 mg, and 10 mg presentations. The approved dosing instructions include chronic dosing and higher dosing during a flare-up, followed by a lower dose after the initial flare-up period (FDA, 2023).

The 5 mg, 20 mg, and 10 mg schedule is most relevant to patients weighing at least 60 kg. The label also contains safety restrictions associated with skeletal maturity and premature epiphyseal closure. These regulatory conditions narrow the practical population even though several patent claims use broader subject language.

Regulatory event Date
FDA approval of Sohonos December 15, 2023
Sponsor Ipsen Biopharmaceuticals, Inc.
Active ingredient Palovarotene
NDA 215034
Dosage form Oral capsules
Therapeutic area FOP and heterotopic ossification

The FDA’s approval was based principally on clinical data from the MOVE study and supporting studies evaluating new heterotopic ossification in patients with FOP.

What is the Orange Book status of U.S. Patent 10,864,194?

U.S. Patent 10,864,194 is associated with the palovarotene product patent estate and is relevant to Orange Book-listed protection for Sohonos. The patent is a method-of-use patent. It does not primarily protect the palovarotene molecule itself or a capsule excipient system.

Public patent records identify the patent as:

Field Information
Patent U.S. 10,864,194 B2
Title Methods of treating fibrodysplasia ossificans progressiva
Patent holder Clementia Pharmaceuticals Inc.
Current commercial owner Ipsen group
Issue date December 15, 2020
Patent type Method of treatment
Active ingredient Palovarotene
Therapeutic area FOP and heterotopic ossification
Reported expiration April 5, 2037

The terminal expiration date should be distinguished from orphan-drug exclusivity. Patent expiration and FDA regulatory exclusivity arise under separate legal authorities. A generic applicant may face both barriers, and the expiration of one does not automatically terminate the other.

When does palovarotene lose exclusivity?

Sohonos received orphan-drug exclusivity for FOP. The seven-year orphan-exclusivity period runs from FDA approval and is expected to extend to December 15, 2030 for the approved FOP indication, subject to statutory exceptions such as inability to assure sufficient quantities or the sponsor’s inability to provide the product (FDA, 2023; 21 U.S.C. § 360cc).

The principal exclusivity dates are therefore:

Protection Expected end date
Orphan-drug exclusivity for approved FOP indication December 15, 2030
U.S. Patent 10,864,194 April 5, 2037
Earliest practical date without successful patent challenge After applicable patent and regulatory barriers expire

Patent protection extends materially beyond orphan exclusivity. A generic applicant could potentially file an abbreviated new drug application before 2037 with a Paragraph IV certification, but commercial launch would create litigation risk if Ipsen sued within the statutory period.

What Paragraph IV challenges and patent litigation affect Sohonos?

No publicly identified Paragraph IV litigation or settlement involving U.S. Patent 10,864,194 is reflected in the cited FDA and patent records. The absence of a public case does not eliminate future challenge risk.

A generic applicant seeking approval before patent expiration could certify that the patent is invalid, unenforceable, or will not be infringed. Ipsen could then bring an infringement action under the Hatch-Waxman framework. A timely suit could trigger a 30-month stay of approval, subject to statutory exceptions and court action.

The strongest potential generic arguments would likely focus on:

  1. Obviousness of adapting the flare-up dosing sequence from clinical protocols.
  2. Written description and enablement for all claimed treatment durations.
  3. Whether the claimed symptom-triggered transition is sufficiently definite.
  4. Whether the claimed regimen is patentably distinct from earlier retinoid or palovarotene treatment disclosures.
  5. Whether the proposed generic label induces infringement of the flare-up regimen.

Ipsen’s strongest counterarguments would be:

  • The specific 5/20/10 mg sequence was clinically selected for FOP.
  • The dosing transition is tied to flare-up symptoms and duration.
  • The regimen addresses a rare disease with a defined and clinically meaningful treatment objective.
  • The claims cover both exact doses and tolerance ranges.
  • The approved label may reproduce the claimed treatment instructions closely enough to support induced infringement.

How strong is the patent estate for palovarotene?

The patent estate is strongest against a generic seeking to copy the FDA-approved FOP dosing instructions. It is less comprehensive against alternative clinical or commercial strategies.

Estate characteristic Assessment
Composition-of-matter protection Not the primary protection provided by U.S. 10,864,194
Core dosing protection Strong overlap with approved 5/20/10 mg regimen
Flare-up treatment protection Strong where the label directs symptom-triggered escalation
Formulation protection Not established by the supplied claims
Manufacturing protection Not established by the supplied claims
Method-of-use protection Central patent value
Biosimilar exposure Not applicable; palovarotene is a small molecule
Generic exposure Relevant after or through Paragraph IV challenge
Design-around flexibility Moderate because claims require a specific sequence and timing

The patent does not prevent every use of palovarotene. A competing product could seek a different disease indication, different dose, different flare-up definition, different duration, or a regimen that avoids one or more claim limitations. Such a product could still face other patents, regulatory barriers, or induced-infringement theories.

What formulations are protected by U.S. 10,864,194?

The supplied claims do not claim a particular formulation. They cover oral administration of palovarotene or a pharmaceutically acceptable salt. They do not specify:

  • Capsule composition
  • Excipient identity
  • Particle size
  • Solid-state form
  • Polymorph
  • Dissolution profile
  • Bioavailability enhancement
  • Controlled-release technology
  • Manufacturing process

The formulation claim language is therefore broad as to the dosage form but limited to oral administration. A generic oral palovarotene capsule could fall within the method claims if its label instructs the claimed dosing regimen. A nonoral formulation would not satisfy the express oral-administration limitation.

Does the patent create biosimilar risk?

No. Palovarotene is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.

The principal generic barriers are:

  • Orphan-drug exclusivity through approximately December 2030.
  • Patent protection reported through April 5, 2037.
  • Potential Orange Book certification litigation.
  • Difficulty designing a label that omits the claimed FOP regimen while still obtaining approval for the same indication.

What licensing deals affect the patent?

Clementia Pharmaceuticals developed palovarotene and was acquired by Ipsen in 2019. The acquisition transferred Clementia’s palovarotene assets, including the FOP development program and associated intellectual property, to Ipsen. Ipsen is the relevant commercial and patent owner for Sohonos in the United States (Ipsen, 2019).

No separate public license is necessary to explain Ipsen’s U.S. position. The principal transaction affecting ownership is Ipsen’s acquisition of Clementia.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiration

This is the lowest-risk scenario. A generic applicant waits until the relevant patent and orphan-exclusivity barriers have expired, subject to any remaining patents or regulatory exclusivities.

Scenario 2: Paragraph IV challenge

A generic applicant files before April 2037 and alleges that U.S. 10,864,194 is invalid, unenforceable, or not infringed. Ipsen may sue, potentially delaying approval through the Hatch-Waxman litigation process.

Scenario 3: Carve-out or skinny label

A generic applicant may attempt to omit patented method-of-use information from its label. This strategy is difficult if the approved indication and dosing instructions inherently direct the 5/20/10 mg regimen. The feasibility depends on FDA labeling requirements and whether the omitted use can be separated from the remaining approved indication.

Scenario 4: Noninfringing alternative regimen

A competitor could pursue a different dose or flare-up schedule. This approach may avoid literal infringement but would require separate clinical support and FDA approval. It may also encounter other patents in the palovarotene estate.

How does U.S. 10,864,194 compare with a composition or formulation patent?

A composition-of-matter patent generally provides broader commercial control because it can cover use of the molecule regardless of indication or dose. U.S. 10,864,194 is narrower. It requires a particular disease, therapeutic purpose, oral route, symptom-triggered transition, dose sequence, and treatment duration.

Its value is therefore concentrated in the approved FOP regimen. The patent is commercially important because the method claim aligns with product labeling, but it does not independently block every palovarotene product.

Key Takeaways

  • U.S. Patent 10,864,194 protects a symptom-triggered palovarotene regimen for FOP.
  • The core sequence is 5 mg daily during quiescence, 20 mg daily for about 28 days during a flare-up, and 10 mg daily afterward.
  • Claim 1 covers dose tolerances and multiple treatment durations.
  • Claim 3 more narrowly tracks the 5/20/10 mg commercial regimen.
  • Claims 11, 12, 22, and 23 add important patient-population limitations involving weight and skeletal maturity.
  • The patent is a method-of-use patent, not a primary composition, formulation, or manufacturing patent.
  • Sohonos received FDA approval on December 15, 2023, with orphan exclusivity expected through December 15, 2030.
  • Public patent records report expiration of U.S. 10,864,194 on April 5, 2037.
  • Palovarotene faces generic rather than biosimilar competition.
  • No public Paragraph IV litigation or settlement involving this patent is identified in the cited records.
  • The main generic vulnerability is claim narrowness. A competing regimen that avoids the required dose sequence, timing, symptom trigger, or patient limitation could reduce infringement exposure.

FAQs About U.S. Patent 10,864,194 and Palovarotene

Is U.S. Patent 10,864,194 a patent on Sohonos itself?

No. It is principally a method-of-treatment patent covering specified palovarotene dosing regimens for FOP.

Does the patent cover palovarotene for every FOP patient?

No. Several claims include specific dose sequences and durations. Dependent claims add limitations involving weight, skeletal maturity, flare-up symptoms, antihistamines, and emollients.

Can a generic sell palovarotene before 2037?

Potentially, but it would need to overcome applicable orphan exclusivity and patent barriers, usually through a Paragraph IV challenge, a successful noninfringement position, or a valid label carve-out.

Does a different flare-up dose automatically avoid infringement?

No. It may avoid literal infringement of the claimed dose limitation, but the full claim set, equivalents, other patents, and the proposed product label would determine overall exposure.

Is palovarotene subject to biosimilar competition?

No. Palovarotene is a small-molecule drug. Competition would proceed through the generic-drug framework, principally an ANDA.

References

  1. Food and Drug Administration. (2023, December 15). FDA approves first treatment for fibrodysplasia ossificans progressiva. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-fibrodysplasia-ossificans-progressiva

  2. Food and Drug Administration. (2023). Sohonos (palovarotene) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215034s000lbl.pdf

  3. United States Patent and Trademark Office. (2020). U.S. Patent No. 10,864,194, methods of treating fibrodysplasia ossificans progressiva. https://patents.google.com/patent/US10864194B2/en

  4. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

  5. Ipsen. (2019, April 17). Ipsen completes acquisition of Clementia Pharmaceuticals. https://www.ipsen.com

  6. Orphan Drug Act, 21 U.S.C. § 360cc. https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partB-sec360cc.htm

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,864,194

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-001 Aug 16, 2023 RX Yes No 10,864,194 ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-002 Aug 16, 2023 RX Yes No 10,864,194 ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-003 Aug 16, 2023 DISCN Yes No 10,864,194 ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.